Renal safety and efficacy of i.v. bisphosphonates in patients with skeletal metastases treated for up to 10 years

Oncologist

Volumn 10, Issue 10, 2005, Pages 842-848

  Guarneri, Valentina ^a,c   Donati, Sara ^b   Nicolini, Massimiliano ^a   Giovannelli, Simona ^a   D'Amico, Roberto ^a   Conte, Pier Franco ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b UNIVERSITY OF PISA   (Italy)

^c UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

Bisphosphonates; Bone metastases; Jaw osteonecrosis; Renal safety

Indexed keywords

ANTIMETABOLITE; BISPHOSPHONIC ACID DERIVATIVE; CREATININE; EPIRUBICIN; GEMCITABINE; IBANDRONIC ACID; NAVELBINE; PACLITAXEL; PAMIDRONIC ACID; PLATINUM DERIVATIVE; STEROID; TAXANE DERIVATIVE; TRASTUZUMAB; VINCA ALKALOID; ZOLEDRONIC ACID;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; AGED; ANALYTIC METHOD; ARTICLE; BONE METASTASIS; BONE NECROSIS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CONFIDENCE INTERVAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MULTIPLE MYELOMA; NEPHROTOXICITY; PARAMETER; POPULATION; PRIORITY JOURNAL; PROSTATE CANCER; RETROSPECTIVE STUDY;

ADULT; AGED; AGED, 80 AND OVER; BONE NEOPLASMS; CREATININE; DIPHOSPHONATES; FEMALE; HUMANS; KIDNEY; MALE; MIDDLE AGED; OSTEONECROSIS; RETROSPECTIVE STUDIES;

EID: 31444454571     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.10-10-842     Document Type: Article

References (30)

1. Jemal A, Tiwari RC, Murray T et al. Cancer statistics, 2004. CA Cancer J Clin 2004;54:8-29.
2. Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 2001;27:165-176.
3. Mercadante S. Malignant bone pain: pathophysiology and treatment. Pain 1997;69:1-18.
4. Hillner BE, Ingle JN, Chlebowski RT et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 2003;21:4042-4057.
5. Erratum in: J Clin Oncol 2004;22:1351.
6. Lacerna L, Hohneker J. Zoledronic acid for the treatment of bone metastases in patients with breast cancer and other solid tumors. Semin Oncol 2003;30(suppl 16):150-160.
7. Zojer N, Keck AV, Pecherstorfer M. Comparative tolerability of drug therapies for hypercalcaemia of malignancy. Drug Saf 1999;21:389-406.
8. Bounameaux HM, Schifferli J, Montani JP et al. Renal failure associated with intravenous diphosphonates. Lancet 1983;1:471.
9. Dumon JC, Magritte A, Body JJ. Efficacy and safety of the bisphosphonate tiludronate for the treatment of tumor-associated hypercalcemia. Bone Miner 1991;15:257-266.
10. Markowitz GS, Appel GB, Fine PL et al. Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate. J Am Soc Nephrol 2001;12:1164-1172.
11. Markowitz GS, Fine PL, Stack JI et al. Toxic acute tubular necrosis following treatment with zoledronate (Zometa). Kidney Int 2003;64:281-289.
12. Zazgornik J, Grafinger P, Biesenbach G et al. Acute renal failure and alendronate. Nephrol Dial Transplant 1997;12:2797-2798.
13. Banerjee D, Asif A, Striker L et al. Short-term, high-dose pamidronate-induced acute tubular necrosis: the postulated mechanisms of bisphosphonate nephrotoxicity. Am J Kidney Dis 2003;41:E18.
14. Barri YM, Munshi NC, Sukumalchantra S et al. Podocyte injury associated glomerulopathies induced by pamidronate. Kidney Int 2004;65: 634-641.
15. Rosen LS, Gordon D, Kaminski M et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 2003;98:1735-1744.
16. Saad F, Gleason DM, Murray R et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002;94:1458-1468.
17. Rosen LS, Gordon D, Tchekmedyian NS et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial. Cancer 2004;100: 2613-2621.
18. Kohno N, Aogi K, Minami H et al. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol 2005;23:3314-3321.
19. Body JJ, Diel IJ, Lichinitser MR et al. Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol 2003;14:1399-1405.
20. Bell R, Body JJ, Tripathy D et al. Ibandronate does not affect time to renal function deterioration over 2 years of treatment: phase III trials. Bone 2004;34:S75.
21. Ali SM, Esteva FJ, Hortobagyi G et al. Safety and efficacy of bisphosphonates beyond 24 months in cancer patients. J Clin Oncol 2001;19: 3434-3437.
22. Hortobagyi GN. Progress in the management of bone metastases: one continent at a time? J Clin Oncol 2005;23:3299-3301.
23. Ruggiero SL, Mehrotra B, Rosenberg TJ et al. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004;62:527-534.
24. Durie BG, Katz M, Crowley J. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 2005;353:99-102.
25. Kapitola J, Zak J, Lacinova Z et al. Effect of growth hormone and pamidronate on bone blood flow, bone mineral and IGF-I levels in the rat. Physiol Res 2000;49(suppl 1):S101-S106.
26. Kapitola J, Zak J. Effect of pamidronate on blood flow in oophorectomized rats. Physiol Res 1998;47:237-240.
27. Fournier P, Boissier S, Filleur S et al. Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 2002;62:6538-6544.
28. Wang J, Goodger NM, Pogrel MA. Osteonecrosis of the jaws associated with cancer chemotherapy. J Oral Maxillofac Surg 2003;61:1104-1107.
29. Maerevoet M, Martin C, Duck L. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 2005;353:99-102.
30. Tarassoff P, Csermak K. Avascular necrosis of the jaws: risk factors in metastatic cancer patients. J Oral Maxillofac Surg 2003;61:1238-1239.